Anti Infective Pharmaceuticals Market India

Transcription

1 Anti Infective Pharmaceuticals Market India April 2012

2 Eecutive Summar Market Drivers and Challenges Drug Regulation and Patents Global anti infective pharmaceuticals market was valued at INR. units while in India it was valued at INR. units in The market is epected to grow at a CAGR of m% from to globall and at n% CAGR in India Anti infectives are the largest contributor to India s domestic sales in, contributing around % Drivers: Increasing patient population Increasing number of vaccine approvals Increase in health insurances Introduction of new drugs Phases of clinical trial Approval and licensing of drugs Patents Challenges: Pricing pressure Logistic problems in the vaccine market Competition Highl fragmented market with large number of plaers Major foreign plaers in the market include Gilead inc, Abbott, Glaosmithkline etc Major domestic companies include Ranba, Cipla, Dr. Redd s, Sun Pharmaceuticals, Panacea Biotech, Torrent Pharmaceuticals among others Strategic Recommendations Fora into the adult vaccine market Strategic partnerships with Governmental and private bodies 2

3 Introduction Market Overview Drivers & Challenges Government Initiatives Market Value Chain, Regulation and Patents Competition Strategic Recommendation Appendi 3

4 Indian anti infectives market is epected to witness an enormous growth over the coming ears Indian Market Overview Anti infectives belong to the acute segment which makes up around % of the total pharmaceutical industr Anti infectives are the largest contributor to domestic pharmaceuticals sales, contributing around % Cephalosporins, penicillins and quinolones are ke drug classes among anti infectives, with a share of around % of the countr s anti infectives market Presentl the market has a sie of INR X bn, and is epected to grow at a CAGR of % from In GSK s Augmentin was the highest selling drug with sales of INR Y bn Zifi, Taim,Monocef, Mo, Taim O, Zinacef and Gerimac were the other top selling drugs India has emerged as one of the leading vaccine manufacturer in recent times, producing % of the global health vaccines Pentaim, Variva and Prevenar were the top selling vaccines in Market Sie and Growth INR units e % e e Top pharmaceutical segments anti infectives CVS gastro CNS respirator diabetes pain oncolog e % 1 Source: 4

5 Drivers & Challenges Summar Drivers Increasing patient population Increasing number of vaccine approvals Increase in health insurances Challenges Pricing pressure Logistic problems in the vaccine market Introduction of new drugs 5

6 Government Initiatives Summar Changes in ta structure Control programmes PPP Projects Government Initiatives Reduction in drug prices 6

7 Pharmaceutical value chains involve the entire process from drug discover to drug marketing A pharmaceutical value chain is a chain of activities which are involved in producing drugs, starting with raw materials and ending with the delivered product Drug Discover Drug Development Manufacturing Distribution Sales and Marketing Drug discover involves the identification, snthesis and screening of chemicals for therapeutic efficac Drug development is the process of bringing a new drug to the market once a lead compound has been identified through the process of drug discover Drug manufacturing are the sstems required for the qualit control covering the manufacture and testing of drugs Distribution of a manufactured drug involves the process b which the drug is supplied to the stockists, substockists, hospitals and retail pharmac shops Pharmaceutical marketing, sometimes called medico marketing, is the process of advertising or otherwise promoting the sale of drugs Source: 7

8 Public: Domestic Compan A Compan (1/3) Compan Information Offices and Centres India Corporate Address Tel No. Fa No. Website Year of Incorporation 19 Ticker Smbol Stock Echange NNN Products and Services Categor Pharmaceutical Molecule Development X Road Bangalore Products/Services CVD, CNS, respirator, dermatolog, orthopedics, nutritional, urolog, antiinfectives Infectious diseases, metabolic diseases, inflammator/respirator diseases, and oncolog Ke People Name Person M Person N Person O Person Q Cit A Head Office Designation Founder CFO Head President Source: 8

9 Public: Domestic Compan A Compan (2/3) Financial Snapshot Ke Ratios 10,000 5,000 Financial Summar The compan incurred a net loss of INR mn in FY, as compared to net profit of INR mn in FY The compan reported total income of INR bn in FY, registering an increase of per cent over FY The compan earned an operating margin of per cent in FY a decrease of percentage points over FY The compan reported debt to equit ratio of in FY, an increase of per cent over FY Financial Summar Source: Revenue INR mn 0 Indicators q m Market Capitaliation (INR) Total Enterprise Value (INR) EPS (INR) PE Ratio (Absolute) r n Revenue Profit / Loss s o t p Present Value X units Y units Z units A Profit INR mn p n 0 m Particulars o change Profitabilit Ratios Operating Margin Net Margin Profit Before Ta Margin Return on Equit Return on Capital Emploed Return on Working Capital Return on Assets Return on Fied Assets Cost Ratios Operating costs (% of Sales) Administration costs (% of Sales) Interest costs (% of Sales) Liquidit Ratios Current Ratio Cash Ratio Leverage Ratios Debt to Equit Ratio Debt to Capital Ratio Interest Coverage Ratio Efficienc Ratios Fied Asset Turnover Asset Turnover Current Asset Turnover Working Capital Turnover Capital Emploed Turnover Improved Decline 9

10 Public: Domestic Compan A Compan (3/3) Ke Business Segments Ke Geographic Segments m n o Ke Recent Developments Description News Overview Anti Infectives Pharmaceuticals Ke Initiatives Compan A is an integrated research based compan that produces a wide range of generic medicines Serves customers in over 100 countries with manufacturing facilities in several countries Anti infective drugs and injectibles include Product 1 and Product 2 Is making consistent effort for continual improvement in rural areas with respect to accessibilit of medicines Source: 10

11 Thank ou for the attention The Anti Diabetic Pharmaceuticals Market India report is part of Netscribes Healthcare Industr Series. For more detailed information or customied research requirements please contact: Contact Number: E Mail: sales@netscribes.com Netscribes (India) Pvt. Ltd. is dedicated to disseminating information and providing quick insights on hot industries in India and other emerging markets. Track our new releases and major updates in these industries on About Netscribes Netscribes is a knowledge consulting and solutions firm with clientele across the globe. The compan s epertise spans areas of investment & business research, business & corporate intelligence, content management services, and knowledge software services. At its core lies a true value proposition that draws upon a vast knowledge base. Netscribes is a one stop shop designed to fulfil clients profitabilit and growth objectives. Disclaimer: This report is published for general information onl. Although high standards have been used the preparation, Netscribes (India) Pvt. Ltd. or Netscribes is not responsible for an loss or damage arising from use of this document. This document is the sole propert of Netscribes (India) Pvt. Ltd. and prior permission is required for guidelines on reproduction. 11